Randomized, Placebo-controlled Crossover Study of Dalfampridine Extended-release in Transverse Myelitis.

Despite an average duration of disease of 10 years since the TM attack initially occurred, we found that the drug showed a trend in improving walking speeds in 85% of individuals while receiving D-ER versus 69% while receiving placebo, and met the higher threshold for responder in 33% while receiving D-ER versus only 8% while receiving placebo, although, given the small numbers of participants, this percentage did not reach statistical significance ( p = 0.33).

also in 53,322 other papers